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Background: Recent progress in malaria control has caused renewed interest in mass drug administration (MDA) as
a potential elimination strategy but the evidence base is limited. China has extensive experience with MDA, but it is
not well documented.
Methods: An ecological study was conducted to describe the use of MDA for the control and elimination of
Plasmodium vivax in Jiangsu Province and explore the association between MDA and malaria incidence. Two
periods were focused on: 1973 to 1983 when malaria burden was high and MDA administered to highly endemic
counties province-wide, and 2000 to 2009, when malaria burden was low and a focal approach was used in two
counties. All available data about the strategies implemented, MDA coverage, co-interventions, incidence, and
adverse events were collected and described. Joinpoint analysis was used to describe trends in incidence and the
relationship between MDA coverage and incidence was explored in negative binomial regression models.
Results: From 1973 to 1983, MDA with pyrimethamine and primaquine was used on a large scale, with up to 30
million people in target counties covered in a peak year (50% of the total population). Joinpoint analyses identified
declines in annual incidence, -56.7% (95% CI -75.5 to -23.7%) from 1973–1976 and -12.4% (95% CI -24.7 to 2.0%)
from 1976–1983. Population average negative binomial models identified a relationship between higher total
population MDA coverage and lower monthly incidence from 1973–1976, IRR 0.98 (95% CI 0.97 to 1.00), while
co-interventions, rainfall and GDP were not associated. From 2000–2009, incidence in two counties declined
(annual change -43.7 to -14.0%) during a time when focal MDA using chloroquine and primaquine was targeted
to villages and/or individuals residing near passively detected index cases (median 0.04% of total population).
Although safety data were not collected systematically, there were rare reports of serious but non-fatal events.
Conclusions: In Jiangsu Province, China, large-scale MDA was implemented and associated with declines in high
P. vivax malaria transmission; a more recent focal approach may have contributed to interruption of transmission.
MDA should be considered a potential key strategy for malaria control and elimination.
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Mass drug administration (MDA) is a core strategy used
for the control and elimination of many tropical dis-
eases, including trachoma, lymphatic filariasis, schisto-
somiasis and onchocerciasis [1]. For malaria eradication
in the 1950s and 60s, MDA was advocated by the World
Health Organization (WHO) as a strategy in situations
where more conventional control measures such as in-
door residual spraying (IRS) with dichlorodiphenyltrichlo-
roethane (DDT) had failed to end residual transmission.
Defined as empiric administration of a therapeutic re-
gimen to an entire population or well-defined sub-
population at the same time, MDA campaigns worldwide
utilized a variety of different drugs, regimens and dosing
intervals. Most were associated with declines in incidence
or parasite prevalence during the intervention but did not
focus on species-specific impact [2] and were not designed
to show interruption of transmission [3-5]. Due to con-
cerns about efficacy, operational feasibility, sustainability,
and emergence of drug resistance, MDA fell eventually
out of favour.
Recent progress in malaria control has caused renewed
enthusiasm and interest in MDA as a potential strategy
for elimination and eradication [6,7]. MDA has also been
considered as a strategy to contain the recent emergence
of artemisinin resistance at the Cambodia-Thai and
Thai-Myanmar borders [8,9]. However, recent evidence
to guide MDA as a public health intervention for mal-
aria remains sparse. Since the eradication era, studies of
MDA have been limited [10-12] and large-scale use of
drugs in communities has been focused on targeted
therapies in specific populations such as in intermittent
preventative therapy and seasonal malaria chemopreven-
tion [13,14]. Furthermore, there has been less attention
on MDA specifically for Plasmodium vivax, the species
which becomes the ultimate challenge for most eliminat-
ing countries because it is more resilient than Plasmo-
dium falciparum to standard interventions outside
Africa [15]. Plasmodium vivax is able to persist in a dor-
mant liver (hypnozoite) stage and relapse over long in-
tervals of months to years. Primaquine, the only drug
widely available for radical cure has variable efficacy and
poor adherence due to the long treatment course re-
quired and concerns about potential life-threatening
haemolysis in persons with underlying glucose-6-
phosphate dehydrogenase (G6PD) deficiency [16]. An ar-
gument for MDA, versus screening and treatment, is that
diagnosis is hampered by the lack of biomarkers for the
liver stage, and limitations of microscopy or rapid diag-
nostic tests (RDTs) to detect blood stage infections
which are characteristically of lower density than P. fal-
ciparum [17]. Furthermore, anopheline mosquito species
that transmit P. vivax tend to be outdoor biting andresting making standard vector control measures such as
bed nets and IRS less effective [18].
China has extensive experience with MDA, including
for P. vivax, but this historical experience focusing spe-
cifically on MDA has not been well documented
[3,4,19,20]. After the eradication era of the 1950s and
60s, falciparum malaria was eliminated from large parts
of the country. But, the challenge of P. vivax persisted,
particularly in the form of resurgences in central China
occurring approximately every decade [21-27]. In the
1970s and 80s large-scale MDA was used to control
these epidemics. In the 1990s and thereafter, a focal ap-
proach was used. The goal of this study was to docu-
ment this MDA experience with P. vivax, focusing on
Jiangsu Province for two time periods for which detailed
records were available. The first period from 1973-1983
began with large P. vivax outbreaks which had been oc-
curring since the Cultural Revolution (1965–68), during
which time civil disturbances resulted in the abandon-
ment of anti-malarial activities [21,22]. Mass drug ad-
ministration was performed on a large scale involving
millions of people. The second period focuses on 2000-
2009, which began with an outbreak of P. vivax malaria
in nearby Anhui Province and bordering areas of Jiangsu
[28]. Focal MDA was performed on a smaller scale, tar-
geted to close contacts, households and villages of index
cases. The impact of MDA on incidence is also explored,
acknowledging limitations of an ecological study design,
which can show associations and generate hypotheses
but cannot prove causality.Methods
Study design
An ecological study was performed to describe the use of
mass drug administration for control and elimination of P.
vivax malaria in Jiangsu Province, China (Figure 1A), and
to explore the impact on malaria incidence. While MDA
had been used since the 1950s, two periods identified by
the provincial malaria programme as having detailed re-
cords available were focused on: a) 1973 to 1983 with
MDA to target counties in the province, and b) 2000 to
2009 with focal MDA to villages and close contacts of
index cases in select counties during a P. vivax epidemic.
As individual level data on malaria cases and compliance
with MDA and other interventions were not available,
population level figures were utilized.MDA methodology, 1973–1983
The goal of seasonal MDA with pyrimethamine and prima-
quine was to treat potential reservoirs of P. vivax blood and
liver stage infection before the start of the malaria transmis-
sion season. Plasmodium falciparum had nearly been
A B
C D
Figure 1 Incidence maps of Jiangsu Province, 1973-1983. A) Map of China showing location of Jiangsu Province, B) Prefecture level incidence
in Jiangsu Province, 1973, C) Prefecture level incidence in Jiangsu Province, 1976, D) Prefecture level incidence in Jiangsu Province, 1983.
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for fewer than 140 annual cases reported (Table 1).
Villagers were notified prior to the annual campaign.
Community health workers and local public health officers
administered medications daily by directly observed therapy
(Figure 2A). MDA was administered before or at the start
of the malaria transmission season that typically begins in
April. From 1973 to 1976, seasonal MDA using pyrimeth-
amine and primaquine was directed at all rural counties,
and from 1977 to 1983, a stratified approach using chloro-
quine and primaquine was implemented (Table 2).
MDA methodology, 2000–2009
From 2000–2009, focal “spring treatment” was adminis-
tered in counties on the western border as response to aP. vivax epidemic due to larger outbreaks in nearby An-
hui Province. Initially, entire natural villages (population
~20 persons, the division below an administrative vil-
lage) were targeted. As incidence declined, more focal
approaches were taken based on the provincial mandate
(Table 2). Exclusion criteria included: age < one year,
pregnancy, serious heart, liver or kidney disease, fever,
and history of cyanosis, systemic bleeding, or dark
coloured urine.
MDA was conducted by local hospital and health bureau
workers in the homes of targeted individuals. Informed con-
sent was conducted verbally and through a handout. Vil-
lagers were instructed to have food before taking the
medication. The administration of drugs was by directly ob-
served therapy (Figure 2B) and documented by collecting pa-
tient signatures. Medication was stopped if serious adverse
Table 1 Jiangsu province, 1973-1983: annual malaria cases and intervention coverage
Year Total
Population























1973 54,703,334 13 6,216,128 113.6 13,389,482 (24.5) 2 14,414,382 (3.3) 0 (0) 0 (0)
1974 54,252,430 4 3,341,110 61.6 17,746,954 (32.7) 5 23,926,883 (5.5) 0 (0) 0 (0)
1975 55,976,643 3 855,105 15.3 27,974,966 (50.0) 33 39,737,778 (8.9) 0 (0) 0 (0)
1976 56,630,708 137 359,371 6.3 27,329,972 (48.3) 76 44,185,317 (9.8) 237,376 (0.1) 0 (0)
1977 57,373,529 110 417,393 7.3 16,534,356 (28.8) 40 39,602,226 (8.6) 72,934 (0.0) 0 (0)
1978 58,025,577 13 640,434 11.0 10,591,797 (18.3) 17 38,866,265 (8.4) 466,594 (0.2) 42,744 (0.1)
1979 58,617,708 39 528,914 9.0 12,740,820 (21.7) 24 30,009,631 (6.4) 3,100,570 (1.3) 49,705 (0.1)
1980 58,921,850 135 377,166 6.4 11,787,687 (20.0) 31 25,034,512 (5.3) 4,156,676 (1.8) 84,425 (0.1)
1981 59,695,818 29 401,556 6.7 6,780,603 (11.4) 17 13,387,109 (2.8) 5,142,527 (2.2) 147,348 (0.2)
1982 60,466,585 67 252,832 4.2 5,503,181 (9.1) 22 9,533,912 (2.0) 5,840,737 (2.4) 142,066 (0.2)
1983 60,223,458 126 128,458 2.1 4,446,687 (7.4) 35 5,504,112 (1.1) 80,804 (0.0) 391,795 (0.7)
Pf Plasmodium falciparum, Pv P. vivax.
aTotal amount of pyrimethamine prophylaxis given for the year. Administration was every two weeks June to October.
bTotal amount of drug salts given for the year. Administration was monthly June to September.
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The goal was for 85% of individuals infected in the previous
year to complete the full course and for 80% of other individ-
uals (family, neighbours, etc.) to complete the full course. All
medication administration and data collection were to be
completed by the end of March of that year [29].Data collection
1973–1983
Aggregate data from all 11 prefectures of Jiangsu Prov-
ince were collected including monthly and annual inci-
dence of reported malaria cases, annual number of
people reached with MDA using pyrimethamine and
primaquine prior to the malaria transmission season, an-
nual prefecture population (based on annual census
data), annual quantities of drug salts and other prophy-
lactic medications administered, and vector control mea-
sures [30]. Protocols and reports on haemolysis or other
adverse events relating to MDA were reviewed.2000–2009
Aggregate data were gathered from two counties (the
administrative level below prefecture) in the western
part of Jiangsu where focal MDA was implemented and
detailed records were available: Sihong in Suqian prefec-
ture and Xuyi in Huaian prefecture (Suquian and Huaian
previously combined and known as Huaiyin prefecture)
[31,32]. The data included monthly and annual inci-
dence, as well as number of subjects that were targeted
and successfully completed a MDA course. Data onadverse events and coverage of vector control measures
were only available from Sihong. Annual population was
available for all townships (administrative level below
county) within Sihong and 22 of 28 in Xuyi [33,34]. For
missing data, populations were imputed based on aver-
age township population that year. Published literature
as well as county and provincial records were reviewed
for any data on haemolysis or other adverse effects relat-
ing to focal MDA.
For both time periods, gross domestic product (GDP)
data from China were collected from the World Bank and
deflated to year 2000 US$ to account for inflation. All
monthly rainfall data were collected from the International
Research Institute for Climate and Society [35]. For the
1978 to 1983 period, monthly rainfall data were calculated
as the average from 14 weather stations throughout
Jiangsu Province. For the 2000 to 2009 period, average
monthly rainfall data were collected from two weather sta-
tions closest by coordinates to the selected counties.Data management and analysis
Data were extracted from paper records with support of
a translator, and then double entered into Microsoft
Excel (Microsoft Corp, Seattle, USA). Data were cleaned
and analysed in R (Foundation for Statistical Computing,
Vienna, Austria) and Stata 11.0 (Stata Corp, College Sta-
tion, TX, USA).
Total MDA coverage was defined as per cent of the
total population covered by MDA (total population
coverage). This value did not take into account the fact
Figure 2 Mass drug administration to villagers by directly observed therapy. A) Xuzhou prefecture 1974, B) Sihong county 2009.
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ceived MDA. Therefore, target population coverage, or
per cent of the target population covered by MDA for
the 2000-2009 dataset (data not available for 1973-1983
dataset) was also presented. Also, as a functional meas-
ure that has relevance to operations and implementa-
tion, particularly for focal MDA where only villages or
household members and neighbours are treated, the ra-
tio of population receiving MDA to incident case was
also calculated.Given that incidence rate appeared to vary over the
study time period, trends were analysed using joinpoint
regression analysis, a statistical method that fits a series
of joined straight lines to rates over time and chooses
best-fitting points or joinpoints where the rate of in-
crease or decrease changes significantly [36]. The grid
search method was used to detect segments best de-
scribing the data. This method creates a “grid” of all pos-
sible locations for joinpoints and tests the error sum of
squares at each one to find the best possible fit.
Table 2 Stratification for seasonal mass drug administration
Time period Incidence
in year prior
Target population Daily drug regimen (adult dose)
MDA, Jiangsu Province, 1973-1976
1973-1976 n/a All rural counties pyrimethamine 50 mg × 2d + primaquine 30 mg × 4d
1977-1983 ≥5% Entire county pyrimethamine 12.5 mg + primaquine 22.5 mg × 8d
<5% Index cases from past year with family and neighbors
Focal MDA, Select counties, 2000-2009
2000-2006 ≥1% Entire village chloroquine 400 mg × 3d + primaquine 22.5 mg × 8d
<1% Index cases from past 2 y with family, IFAT positive
individuals from past 2 y
2007 ≥1% Entire village chloroquine 400 mg × 3d + primaquine 22.5 mg × 8d
<1% but >1 case Index cases from past 2 y with family and neighbors
1 case Index cases and IFAT positive individuals from past 2 y primaquine 22.5 mg × 8d
2008 ≥3% Entire village chloroquine 400 mg × 3d + primaquine 22.5 mg × 8d
1-3% Index cases from past year with family and neighbours
<1% Index cases from past year with family, IFAT positive
individuals from past year
primaquine 22.5 mg × 8d
2009 2-3 cases Index cases from past year with family and neighbours chloroquine 400 mg × 3d + primaquine 22.5 mg × 8d
1 case Index case from past year primaquine 22.5 mg × 8d
IFAT indirect fluorescent antibody test, IFAT surveys as a measure of past exposure were performed in select townships. In Sihong, number of IFAT positive
individuals treated was 24 in 2006, 13 in 2007, and six in 2008. Village refers to a natural village, the administrative level below an administrative village.
Drug regimens are recorded as adult dosages though age adjusted doses were given to children.
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change in trend was detected over the study period. An-
nual per cent change with 95% CI for each segment are
reported to describe linear trends by period.
For the 1973-1983 Jiangsu Province dataset, the associ-
ation between annual total population MDA coverage and
incidence was estimated using population average negative
binomial models. To control for background incidence
trend as a potential confounder, an interaction term for
time period was included based upon segments identified
in the joinpoint analysis: early (1973-1976) vs later (1977-
1983). A Poisson model was considered but not used as
the negative binomial distribution provided a better fit for
the data given the high amount of over-dispersion. The
negative binomial analysis modelled monthly counts
(monthly cases of P. vivax) as the outcome, taking into ac-
count prefecture population as an offset. Regression coeffi-
cients were computed as incidence rate ratios (IRRs).
Total annual population MDA coverage was the primary
exposure variable and other covariates controlled for in-
cluding: annual chemoprophylaxis coverage, net coverage
(defined as the number of nets distributed per population),
rainfall lagged by one month, and deflated GDP. Drug
salts were not included in the model due to non-
significant effect and collinearity with chemoprophylaxis
and bed nets. Generalized estimating equations with anautoregressive correlation structure were used to control
for serial correlation within prefecture time series.
Monthly and prefecture dummy terms were used to con-
trol for seasonality effects beyond rainfall and unobserved
prefecture fixed effects, respectively. To control for poten-
tial spatial endogeneity between prefectures, the model in-
cluded anomalies for intervention terms (computed as the
difference between annual coverage and the local mean
coverage over the study period for each prefecture). Rain-
fall and GDP values were standardized to represent one
standard deviation (by subtracting the mean and dividing
by the standard deviation).To evaluate the association be-
tween MDA and incidence during different time periods,
a binary term for early (1973-1976) vs. later (1977-1983)
years was interacted with the MDA term. Confidence in-
tervals (CI) of 95% are presented based upon robust stand-
ard errors. Due to low total population coverage and
incidence, the model was not applied to the 2000-2009
county datasets.
Ethical issues
Human subjects’ approval was not indicated because the
surveillance data utilised was existing, aggregate and
without personal identifiers. The analysis protocol was
reviewed by the Centers for Disease Control and Preven-
tion IRB and received non-research determination.
Hsiang et al. Malaria Journal 2013, 12:383 Page 7 of 14
http://www.malariajournal.com/content/12/1/383Results
1973–1983, MDA, Jiangsu province
MDA coverage
Total population coverage of seasonal MDA increased
from 24.5% in 1973 to 50% in 1975, then gradually de-
clined to 7.4% in 1983 (Table 1). At peak coverage in
1975, almost 30 million people were treated. The median
number of individuals who received MDA for every inci-
dent case of P. vivax malaria the previous year was 24,
ranging from 2 in 1973 to 76 in 1976.
Other interventions
In almost all prefectures, intermittent chemoprophylaxis was
used during the transmission season from June to October.
The regimen consisted of either pyrimethamine 50 mg every
two weeks or chloroquine 300 mg every ten days. Per cent
population coverage of chemoprophylaxis increased from
3.3% in 1973 to 9.8% in 1976, then declined to 1.1% by 1983.
At the height of the programme, up to 44 million cumulative
doses were administered a year. From 1976 to 1983, a few
prefectures also distributed salt fortified with pyrimethamine.
From June to September, each person received a monthly
average of 400 g salt containing 157.5 mg pyrimethamine
[37]. Population coverage was highest at 2.4% in 1982. Bed
nets were utilized beginning in 1978, however population
level coverage was very low. Indoor residual spraying was
not part of the provincial malaria strategy.
Treatment for clinical malaria cases varied by county.
The most commonly used regimen was chloroquine onFigure 3 Monthly incidence and total population of mass drug admin
Province, 1973-1983.days 1-3 (1.2 g total) with primaquine on days 1-4
(22.5 mg daily). One month later patients were treated
with primaquine for another four days (22.5 mg daily)
for a total primaquine dose of 180 mg. Another regimen
used was chloroquine on days 1-3 (1.2 g total) with
primaquine on days 1-8 (22.5 mg daily, 180 mg total).
From 1973 to 1977, a five-day regimen was also used
in some counties, chloroquine on days 1-3 (1.2 g
total) with primaquine on days 1-5 (22.5 mg daily,
112.5 mg total). Subjects who were infected in the
previous year were also individually targeted for sea-
sonal MDA.
MDA and incidence
In the setting of large scale MDA, the incidence of P.
vivax in Jiangsu Province declined from 113.6 in 1973 to
2.1 per 1,000 population in 1983 (Table 1, Figures 1B-
1D, 3). Joinpoint analysis on the aggregate provincial
dataset identified two distinct periods: 1973-1976 when
annual per cent change was -56.7% (95% CI -75.5 to
-23.7%) and 1976-1983 when annual per cent change
was -12.4% (95% CI -24.7 to 2.0%). At the prefecture
level, no more than two distinct periods were identified,
with joinpoint breaks occurring from 1976 to 1978. In
most prefectures, annual per cent changes in incidence
were negative (Table 3).
The population average negative binomial model con-
firmed that time period significantly impacted the rela-
tionship between total population MDA coverage andistration, chemoprophylaxis and drug salts, Jiangsu
Table 4 Coefficient estimates of population average
negative binomial models predicting monthly cases
Parameter Incidence rate ratio (IRR) and 95% CI
(n = 11 prefectures)
(1977-1983) vs (1973-1976)a 0.19b (0.11 to 0.33)
Annual MDA: (1973-1976)a 0.98c (0.97 to 1.00)
Annual MDA: (1977-1983)a 1.05b (1.03 to 1.06)
Annual chemoprophylaxis 0.98 (0.96 to 1.00)
Bed nets per person 1.03 (0.94 to 1.13)
Rainfall (lagged 1 month) 1.02 (0.98 to 1.06)
GDP 0.95 (0.87 to 1.04)
n (prefecture-months) 1452
Models include month dummies to control for seasonality and prefecture





Table 3 Joinpoint analysis for malaria incidence trends in
Jiangsu province
MDA 1973−1983 Segments Annual per cent change (95% CI)
Province−wide 1973–1976* −56.7 (−75.5 to −23.7)
1976–1983 −12.4 (−24.7 to 2.0)
Prefectures
Changzhou 1973–1983* −33.8 (−36.7 to −30.8)
Huaiyin 1973–1983* −19.9 (−33.0 to −4.2)
Lianyungang 1973–1983* −24.3 (−38.2 to −7.3)
Nanjing 1973–1978 9.5 (−35.2 to 85.1)
1978–1983* −19.7 (−28.6 to −9.7)
Nantong 1973–1977* −65.5 (−75.8 to −50.9)
1977–1983 −6.1 (−22.3 to 13.5)
Suzhou 1973–1976 −8.6 (−40.2 to 39.8)
1976–1983* −35.7 (−42.6 to −28.0)
Wuxi 1973–1983* −40.2 (−43.1 to −37.2)
Xuzhou 1973–1983* −24.2 (−38.8 to −11.9)
Yancheng 1973–1976* −71.6 (−84.1 to −49.3)
1976–1983* −18.6 (−30.2 to −4.8)
Yangzhou 1973–1976* −67.6 (−82.2 to −41.1)
1976–1983 −1.4 (−15.9 to 15.8)
Zhenjiang 1973–1977* −44.2 (−56.2 to −28.9)
1977–1983* −28.1 (−36.8 to −18.1)
Focal MDA 2000−2009
County
Sihong 2000–2009* −27.0 (−35.6 to −17.2)
Xuyi 2000–2002* −43.7 (−65.7 to −7.8)
2002–2009* −14.0 (−24.8 to −1.7)
*statistically significant.
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the later period compared with the earlier period (IRR =
0.19; 95% CI 0.11 to 0.33), after controlling for potential
confounding factors including chemoprophylaxis, bed
nets, rainfall, and GDP (Table 4). Between 1973 and
1976, higher total population MDA coverage was associ-
ated with significantly lower monthly incidence (IRR =
0.98; 95% CI 0.97 to 1.00) after controlling for con-
founders, but in the later period, it was associated with
higher incidence (IRR = 1.05; 95% CI 1.03 to 1.06). Other
potential confounders were not significantly associated
with monthly incidence.
Safety
Adverse events from MDA were not systematically moni-
tored as part of the programme, but five reports docu-
menting G6PD deficiency-related severe adverse events
from primaquine were identified (Table 5). Two case series
were recorded in the setting of large-scale campaigns, one
from 1975 and one from 1976. There were two cross-sectional studies, one among family members of patients
with severe G6PD deficiency and one among high-risk
groups. Additionally, there was a case report from 1979.
In the two case series, drugs were administered to
254,910 residents in Jinhu county and 44,589 residents
of Liuhe county. The incidence of acute haemolysis was
3.5 and 9.3 per 100,000 population, respectively. Symp-
toms were typical for acute haemolytic reaction. Among
the 40 patients from Liuhe county, G6PD deficiency
testing was performed using the methaemoglobin reduc-
tive test, which had a sensitivity of 65% for detection of
patients with acute haemolysis. In both studies, there
were no deaths and all patients recovered with drug dis-
continuation and supportive care.
In one of the cross-sectional studies, methaemoglobin
testing was performed in 94 family members of three pa-
tients who suffered from haemolysis after primaquine
and 59.6% tested positive. In another study, methaemo-
globin testing was performed in groups hypothesized to
have higher prevalence of G6PD deficiency. The preva-
lence of a deficiency was 5.7% in a village with a high in-
cidence of acute haemolysis versus 0.7-1.0% in the other
groups (a village with past P. falciparum cases and a vil-
lage with members of the Hui minority group) and 0%
in a control group of patients with liver disease. The
higher prevalence in the village with a high incidence of
acute haemolysis was thought to be due to a genetic pre-
disposition in this community.
2000–2009, focal MDA, Sihong and Xuyi counties
Focal MDA coverage
Utilizing the stratified strategy, total population coverage
was low. In 2001, it was 1.21% in Sihong and 0.21% in
Xuyi, then dropped to very low levels by 2003 (Figure 4).
On the other hand, target population coverage was
Table 5 Summary of acute haemolysis reports, Jiangsu province
Study design Methods Findings
Case series [38] Setting: 1975, Jinhu county, Huaiyin prefecture, 254,910
residents given primaquine (22.5 mg daily × 8 days) and
pyrimethamine (50 mg daily × 2 days), Incidence of
haemolysis: 3.5/100,000
Baseline characteristics of affected patients: 8 of 9 were male,
mean age 14.4 (range 5 to 38), two brothers with history of
favism.
Methods: clinical course described in nine patients with
acute haemolysis
Haemolysis on day 2 or 3 after cumulative dose of 45 mg in 2
adults and after 15-30 mg in children (ages 5 to 15)
Symptoms: haematuria, weakness, fever, appetite loss, abdominal
pain/discomfort, dizziness and headache, bruising, epistaxis
Patients recovered with drug discontinuation, transfusions,
and supportive care
Case series [39] Setting: 1976, Linhe county, Nanjing prefecture, 444,589
residents given primaquine (30 mg daily × 4 days) and
pyrimethamine (50 mg daily × 2 days), Incidence of
haemolysis: 9.3/100,000
Baseline characteristics of affected patients: 32 of 40 were
male, age range 4 to 62, 65% were <15 y, 20% with history of
favism, 15% with family history of haemolysis
Methods: collected clinical data in 40 patients with acute
haemolysis (more detailed data from 18 hospitalized
patients), methaemoglobin reductive testing in 80 family
members (immediate and spouse) and 29 healthy controls
Haemolysis in 18 hospitalized patients: 56% onset 1-2 days after
medication. Haemoglobin levels (g/dL): 3-5: 12 patients, 5.2-6.5:
7 patients, 7.5: 1 patient (unclear if repeated measured included)
Symptoms: jaundice (18), fever (17), loss of appetite (14),
weakness (12), dizziness (11), haematuria (9), dark coloured
urine (8), abdominal pain (7), cyanosis (7), and headache (7)
Deficiency by methaemoglobin testing: 65% of patients
tested one month after haemolytic event, 28/50 (56%) female
family including 12 of 29 mothers tested and 11 of 17
mothers of male patients, 6/30 (20%) male family (age range
of male or female family members: 6-70 y), 0% in adult con-
trols (53.8% male); deficiencies were medium except severe in
2 patients and 2 family members
Household clustering rare (1 household with 3 cases, 2
households with 2 cases)
Cross-sectional survey [40] Setting: as above
Methods; methaemoglobin reductive testing in family
members of 3 patients who had haemolysis after
primaquine, 94/141 family members agreed to
participate
Deficiency by methaemoglobin testing detected in 59.6%.
Test results by sex (males n = 54, females n = 40):
any deficiency: 51.9% in males vs 70.0% in females,
serious deficiency: 51.9% in males vs 17.5% in females
Cross-sectional survey [41] Setting: as above but in 1977 following mass drug
administration
Methods: methaemoglobin reductive testing in 1515
subjects from 4 comparison groups Comparison groups:
1) village with high incidence of haemolysis, 2) village
with past P. falciparum cases, 3) village with Hui minority
group, 4) patients with schistosomiasis associated liver
disease or chronic hepatitis. All ≥5 years of age
Prevalence of deficiency: group 1: 5.7% (60/1051, 19 severe), group
2: 3/289 1.0% (1 severe), group 3: 0.7% (1/143), group 4 0% (0/32)
Prevalence of deficiency by sex: males 4.9% vs females 3.8%
(n=689 males and 801 females). Prevalence of deficiency in males
by age: 5-9y 10.5% (n = 58), 10-14y 5.8% (n = 220), 15-18y 3.5%
(n = 114), 19-30y 2.3% (n = 131), 31-60y 5.2% (n = 153), >60y 0.0%
(n = 13). Prevalence of deficiency in females by age: 5-9y 9.7%
(n = 62), 10-14y 3.5% (n = 170), 15-18y 2.5% (n = 120), 19-30y 2.5%
(n = 303), 31-60y 4.5% (n = 224), >60y 0.0% (n = 22)
Case report [42] Setting: 1979, Xinyi county, Xuzhou prefecture
Methods: clinical course described
15 y male diagnosed with vivax malaria based on clinical
symptoms of fever, sweats, headache. Developed fever and
malaise after 2 days of chloroquine (900 mg) and primaquine
(37.5 mg), next day had dark urine, jaundice, nausea,
vomiting, fever, hepatomegaly, haematocrit 35%. Admitted
and recovered with discontinuation of primaquine,
transfusions, and supportive care.
Methaemoglobin reductive testing, severe 0-30%, medium 3175%, normal >75%.
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http://www.malariajournal.com/content/12/1/383generally high. In Sihong, median 91.6% (range 59.5 to
99.2%) completed treatment and in Xuyi, median 92.0%
(range 76.5 to 98.3%) completed treatment. The median
number of individuals who completed MDA for each in-
cident case of P. vivax malaria was 16 (range 5 to 39) in
Sihong and 10 (range 4 to 22) in Xuyi (Table 6).Other interventions
Unlike in the 1973-1983 time period, other prophylactic
drugs were not utilized. In Sihong county, there was
some use of vector control measures. Insecticide-treated
bed nets covered 0 to 3% of the population between
2000 and 2004, 10% in 2005, and 4 to 8% between 2006
AB
Figure 4 Incidence with total population coverage of focal mass drug administration, 2000-2009. A) Sihong county, B) Xuyi county.
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http://www.malariajournal.com/content/12/1/383and 2009. Indoor residual spraying was performed in
2007 and 2009 in select townships. Coverage was re-
corded as 109.5 kg sprayed over 47,706 sq m in 2007
and 231 kg sprayed over 109,125 sq m in 2009. No infor-
mation was available on proportion of structures
sprayed. There was no recorded use of vector control
measures in Xuyi. During this time period, clinical cases
of P. vivax presenting to health facilities were treated
with chloroquine for three days (1.2 mg total dose) and
primaquine for eight days (180 mg total dose).
Focal MDA and incidence
Although the peak incidences were low at baseline, 0.79
and 0.29 per 1,000 population in Sihong and Xuyi, re-
spectively, incidence declined further in the setting of
focal MDA (Figure 4). Sihong and Xuyi counties saw de-
clines the year after focal MDA was started. Low inci-
dences were maintained even as focal MDA coverage
declined. Joinpoint analysis identified two distinct pe-
riods in Xuyi and one in Sihong (Table 3). In Xuyi, the
break correlated with a change in total population cover-
age of focal MDA (Figure 4). Annual per cent changeswere negative and statistically significant in all segments.
Temporally, other factors did not appear to contribute
to decreasing incidence. Gross domestic product in-
creased over the study period but the rate was steady.
Rainfall was highest in 2000, 2005 and 2007 (Additional
file 1: Figures S1b and S2b). Vector control measures
were used in Sihong, but the periods of highest coverage
do not correspond with declines in incidence.
Safety
In Sihong, the number of subjects with adverse reactions
was recorded in 2003 and 2007. Adverse reactions were
few, occurring in five subjects (2.1/1,000) in 2003 and
two (4.3/1,000) in 2007. Symptoms included haemolysis
with primaquine, dizziness, gastrointestinal upset, nau-
sea, and vomiting with chloroquine. Safety data were not
available from Xuyi.
Discussion
MDA is increasingly being considered in the battle
against malaria yet few descriptions of its use for P.
vivax exist in the published literature. This ecological
















2000 979107 477 0.49 0 n/a n/a n/a
2001 999522 788 0.79 12056 1.21 89.6 15
2002 1021073 273 0.27 8330 0.82 88.3 31
2003 1027329 188 0.18 3220 0.31 74.7 17
2004 979866 145 0.15 836 0.09 90.6 6
2005 979866 120 0.12 542 0.06 59.5 5
2006 1002408 93 0.09 730 0.07 92.6 8
2007 1010050 100 0.10 657 0.07 94.5 7
2008 1011239 83 0.08 1032 0.10 94.7 12
2009 1014450 34 0.03 1331 0.13 98.2 39
Xuyi
2000 898854 263 0.29 917 0.10 98.3 4
2001 898854 144 0.16 1928 0.21 76.5 14
2002 898854 84 0.09 1814 0.20 90.4 22
2003 898854 79 0.09 554 0.06 89.5 7.
2004 898854 58 0.06 463 0.05 96.9 8
2005 883533 25 0.03 249 0.03 85.0 10
2006 883533 54 0.06 264 0.03 94.0 5
2007 883533 42 0.05 213 0.02 92.6 5
2008 883533 35 0.04 640 0.07 91.3 18
2009 883533 25 0.03 231 0.03 98.3 9
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largest malaria MDA implementation experience docu-
mented to date. The potential impact of seasonal MDA
on the incidence of vivax malaria in Jiangsu Province,
China was explored. After controlling for potential con-
founders including economic growth, weather, and co-
interventions, it was found that large-scale MDA from
1973-1976 was associated with declines in P. vivax malaria
transmission. In the 2000-2009 data from two counties,
joinpoint analyses showed significant declines in incidence
that temporally appear related to focal MDA and not
other factors. Safety data were not collected systematically
but there were rare reports of serious but non-fatal events.
More recent surveillance data indicate that the declines in
malaria have been sustained. In 2011, 20 of China’s 31
provinces reported no locally acquired malaria cases. In
2012, Jiangsu was one of six additional provinces to report
no locally acquired cases [43]. Thus, the large-scale ap-
proach was associated with declines in high levels of trans-
mission and the more recent focal approach may have
contributed to interruption of transmission.
With the renewed interest and commitment to malaria
elimination, there is growing interest in MDA usingprimaquine because it is the only drug available to treat
the hypnozoite stage of P. vivax, as well as mature game-
tocytes of P. falciparum [44]. Primaquine has been
widely used for MDA, particularly during the eradication
era, but detailed documentation on its use specifically
for P. vivax has been sparse, there are no controlled
studies, and few have demonstrated sustained impact
[2,3,45-51]. This study had similar limitations in that it
was an ecological study and not able to prove impact
given the lack of a control. There is also the possibility
of reverse causation. From 1977-1983, the model showed
a positive association between MDA and incidence, but
this is likely because total population coverage decreased
as incidence declined during this distinct period. Also, in
the later time period, total population coverage was
lower and underestimated the true target population cover-
age to a greater degree. Other potential limitations include
confounding and information bias. However, attempts
were made to control for economic growth, weather and
co-interventions. While it is possible that local officials re-
ported inaccurate coverage and incidence figures, findings
were consistent across several groups (prefecture and
counties) and over a long time period.
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sign enabled exploration of the impact of a population
level intervention on a population level outcome, which
is of obvious public health importance and should
stimulate further scientific endeavours, both for inter-
vention studies and the development of new drugs and
diagnostics for use in MDA. This paper is among the
few to systematically document the MDA experience
from China, where the malaria experience is rich but
poorly documented due to language barriers. It provides
a rare focus on P. vivax, the most large-scale MDA ex-
perience documented (peak coverage reaching 30 million
people), and is the first to describe China’s recent use of
focal MDA.
The optimal timing, frequency, drug(s), target popula-
tion, and target population coverage in MDA are not
clear [8,52]. In Jiangsu, the timing (before the transmis-
sion season) and drugs (antirelapse +/- blood schizonti-
cide) were selected to decrease the reservoir, rather than
to produce an immediate impact on disease burden as
the target population was largely asymptomatic. An
eight-day course of primaquine was chosen based on ef-
ficacy seen in clinical trials and concern that a longer
treatment course would be operationally challenging to
administer via directly observed therapy and less accept-
able to the population [53]. Also, although the treatment
course was shorter than the standard 14-day course rec-
ommended by WHO, the daily dose was higher, and
courses were repeated annually.
The target population was adapted to a changing epi-
demiology. During the higher burden period from 1973-
1976, drugs were administered to entire high-risk coun-
ties and as transmission declined, a stratified approach
was taken to target villages and households of passively
identified index cases (assuming local transmission at
the home residence) and eventually single, high-risk in-
dividuals (e g, subjects positive by indirect fluorescent
antibody test (IFAT) testing). The stratified approach
was undertaken as a way to decrease workload, but more
importantly, to minimize risk and maximize acceptability
in communities that no longer saw malaria as a major
threat. Target population coverage data were not avail-
able for the 1973-1983 programme. However from 2000-
2009, it was generally above 85% in Sihong and Xuyi.
These goal coverage levels are similar to estimated ne-
cessary coverage for P. falciparum elimination [54]. To
help guide MDA operations for P. vivax, future field and
modelling work should aim to determine the minimal
coverage required to achieve an objective (control or
elimination).
As an additional measure of coverage, the ratio of
population receiving MDA to incident case was calcu-
lated. Although this measure has not been used in prior
MDA reports, it is presented as a functional measurethat has relevance to operations and implementation,
particularly for targeted MDA where only villages or
household members and neighbours are treated. From
1973-1983, when MDA was administered to entire
counties, the range was 2 to 76, with the ratio increasing
as incidence declined. With the focal approach used
from 2000-2009, the range was 4 to 39. Operationally,
lower numbers correspond roughly to the size of a
household of an index case, while larger numbers cor-
respond with the involvement of neighboring house-
holds. This ratio could be considered similar to the
concept of number needed to treat (NNT) and future
work is needed to better define the optimal ratio.
A major challenge of primaquine use for MDA is the
risk of haemolysis in patients with underlying G6PD de-
ficiency. In symptomatic cases, testing for G6PD defi-
ciency is not recommended prior to administration of a
single dose to target P. falciparum gametocytes but it is
recommended for a 7- to 14-day regimen for radical
cure of P. vivax [55] and there are no guidelines for use
in MDA of asymptomatic individuals. The reported
prevalence of G6PD deficiency among Han, the predom-
inant ethic group in Jiangsu is low, <5% among males
[56]. In one of the case series study, the reported inci-
dence of haemolysis from mass primaquine administra-
tion was 9.3 per 100,000 population [39]. The authors
note that the incidence was higher than expected and
this may have been because the daily primaquine dose of
30 mg was too high (subsequent campaigns used
22.5 mg) or because the timing of that year’s MDA cam-
paign was later than previous years and coincided with
peak seasonal fava bean consumption. The most com-
parable MDA to those reported here was conducted in
300,000 US soldiers returning from Korea on troopships
in 1952-4 who received 210 mg of primaquine over two
weeks. The severe haemolytic reaction rate was esti-
mated at four per 100,000 in a population that would
have been expected to have a greater prevalence of
G6PD-deficient individuals than in China [57]. No irre-
versible adverse events occurred in the Jiangsu reports,
but the potential risks suggest that in other settings with
similar rates of G6PD deficiency, close monitoring, which
would be possible with daily direct observed therapy,
could be considered. In addition services for urgent blood
transfusion should be available for the few cases that do
haemolyse to very low levels of haemoglobin. Testing for
G6PD deficiency might be focused on patients with a per-
sonal or family history of favism or haemolysis (Table 5)
or performed on a more wide scale once a point of care
G6PD deficiency test becomes available.
Conclusions
There is growing interest for the use of MDA to control
and eliminate malaria but the literature on use specifically
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http://www.malariajournal.com/content/12/1/383for P. vivax is limited. While this study was retrospective
and mainly descriptive, it adds to the evidence base for
seasonal MDA. It presents a little documented experience
from China, where seasonal MDA was practiced (first on
a large scale and later in a focal fashion) and likely contrib-
uted to declines in vivax malaria transmission and rare re-
ported adverse events. Ongoing research is needed to
develop a safer and more effective drug, but there are
likely settings where MDA using primaquine could be ap-
plied now with a logical and safe operational design and
evaluated through a phased approach. MDA should be
considered as a potential strategy to hasten and achieve
malaria elimination, and not remain something of only
historical interest.
Additional file
Additional file 1: Economic indicators and monthly rainfall.
Abbreviations
CI: Confidence interval; G6PD: Glucose-6-phosphate dehydrogenase;
GDP: Gross domestic product; IFAT: Indirect fluorescent antibody test;
IRR: Incidence rate ratio; IRS: Indoor residual spraying; MDA: Mass drug
administration; RDT: Rapid diagnostic test; UCSF: University of California,
San Francisco; WHO: World health organization.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MSH, QG, RGAF, and GDS conceived the study. MSH, QG and JH designed the
study. ART, YL and MSH collected the data. AB, JH, and MSH analysed the data.
RG, SPK and CJ contributed to the interpretation of the data. MSH, ART, JH, and
AB drafted the paper. All authors reviewed early drafts and contributed to the
final paper. All authors read and approved the final manuscript.
Acknowledgements
This work has been an output of the Asia Pacific Malaria Elimination Network
(APMEN) as well as the Malaria Elimination Group (MEG). Funding for the
work was provided through a grant from the Bill and Melinda Gates
Foundation to the UCSF Global Heath Group (MSH, RGAF, RG) as well as a
grant from the UCSF Pathways Funding Committee Research Fellowship
program (ART). MSH is additionally funded by a National Institutes of Health/
National Institute of Allergy and Infectious Diseases K23 grant (P0045532)
and a Burroughs Wellcome Fund/American Society of Tropical Medicine and
Hygiene Fellowship Award (P0049395). JH and SPK are funded by the
Centers for Diseases Control and Prevention. YL, JC, and QG are funded by
Jiangsu Province’s Medical High Tech Platform (ZX201108) and Jiangsu
Science and Technology Department (BM2009902). AB is funded by a grant
from the President’s Malaria Initiative. GDS is funded by the Australian
Defence Force. The paper represents the views of the authors and not the
opinion or policy of their organization or the funders.
We thank Huayun Zhou, Julin Li, Weiming Wang, Yaping Gu, Guizhi She,
Song Xu, Yue Tang, and Zhaodong Wang for their support in data collection;
Yuanyuan Cao for support on the maps; Andy Anglemeyer, Allen Hightower,
Ann Lazar, and Jenny Liu for their input in data analysis; Edmund Seto and
Hugh Sturrock for helping to gather weather data; Gavin Yamey for his
review of the paper; and Michael Wang for translation support.
Author details
1Global Health Group, University of California San Francisco (UCSF), San
Francisco, USA. 2Department of Pediatrics, UCSF Benioff Children’s Hospital,
UCSF, San Francisco, CA 94143, USA. 3Malaria Branch, Centers for Disease
Control and Prevention, Atlanta, GA, USA. 4School of Medicine, UCSF, San
Francisco, USA. 5Jiangsu Institute of Parasitic Diseases, Key Laboratory ofParasitic Disease Control and Prevention (Ministry of Health), Jiangsu
Provincial Key Laboratory of Parasite Molecular Biology, Wuxi, China.
6Department of Global Health Systems and Development, Tulane University
School of Public Health and Tropical Medicine, New Orleans, LA, USA.
7Australian Army Institute, Enoggera, Queensland, Australia.
Received: 22 August 2013 Accepted: 24 October 2013
Published: 1 November 2013
References
1. Hotez PJ: Mass drug administration and integrated control for the
world’s high-prevalence neglected tropical diseases. Clin Pharmacol Ther
2009, 85:659–664.
2. Onori E: Experience with mass drug administration as a supplementary
attack measure in areas of vivax malaria. Bull World Health Organ 1972,
47:543–548.
3. von Seidlein L, Greenwood BM: Mass administrations of antimalarial
drugs. Trends Parasitol 2003, 19:452–460.
4. Poirot E, Hwang J, Kachur SP, Slutsker L, Skarbinski J: Mass drug
administration for malaria. Cochrane Database Syst Rev 2010:CD008846.
DOI: 008810.001002/14651858.CD14008846.
5. Greenwood B: The use of anti-malarial drugs to prevent malaria in the
population of malaria-endemic areas. Am J Trop Med Hyg 2004, 70:1–7.
6. The malERA Consultative Group on Drugs: A research agenda for malaria
eradication: drugs. PLoS Med 2011, 8:e1000402.
7. Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, Smith-Gueye
C, Fullman N, Gosling RD, Feachem RGA: The changing epidemiology of
malaria elimination: new strategies for new challenges. Lancet 2013,
382:900–911.
8. Maude RJ, Socheat D, Nguon C, Saroth P, Dara P, Li G, Song J, Yeung S,
Dondorp AM, Day NP, White NJ, White LJ: Optimising strategies for
Plasmodium falciparum malaria elimination in Cambodia: primaquine,
mass drug administration and artemisinin resistance. PLoS One 2012,
7:e37166.
9. World Health Organization: Consideration of mass drug administration for the
containment of artemisinin-resistant malaria in the Greater Mekong subregion,
Report of a consensus meeting, 27-28 September 2010. Geneva, Switzerland:
World Health Organization; 2011.
10. Kaneko A, Taleo G, Kalkoa M, Yamar S, Kobayakawa T, Bjorkman A: Malaria
eradication on islands. Lancet 2000, 356:1560–1564.
11. Song J, Socheat D, Tan B, Dara P, Deng C, Sokunthea S, Seila S, Ou F, Jian H,
Li G: Rapid and effective malaria control in Cambodia through mass
administration of artemisinin-piperaquine. Malar J 2010, 9:57.
12. Von Seidlein L, Walraven G, Milligan PJ, Alexander N, Manneh F, Deen JL,
Coleman R, Jawara M, Lindsay SW, Drakeley C, De Martin S, Olliaro P,
Bennett S, Schim van der Loeff M, Okunoye K, Targett GA, McAdam KP,
Doherty JF, Greenwood BM, Pinder M: The effect of mass administration
of sulfadoxine-pyrimethamine combined with artesunate on malaria
incidence: a double-blind, community-randomized, placebo-controlled
trial in The Gambia. Trans R Soc Trop Med Hyg 2003, 97:217–225.
13. Bardaji A, Bassat Q, Alonso PL, Menendez C: Intermittent preventive
treatment of malaria in pregnant women and infants: making best use
of the available evidence. Expert Opin Pharmacother 2012, 13:1719–1736.
14. Meremikwu MM, Donegan S, Sinclair D, Esu E, Oringanje C: Intermittent
preventive treatment for malaria in children living in areas with seasonal
transmission. Cochrane Database Syst Rev 2012, 2, CD003756.
15. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM,
Sabot O, Rodriguez MH, Abeyasinghe RR, Ghebreyesus TA, Snow RW:
Shrinking the malaria map: progress and prospects. Lancet 2010,
376:1566–1578.
16. John GK, Douglas NM, von Seidlein L, Nosten F, Baird KJ, White NJ, Price RN:
Primaquine radical cure of Plasmodium vivax: a critical review of the
literature. Malar J 2012, 11:280.
17. Douglas NM, John GK, von Seidlein L, Anstey NM, Price RN:
Chemotherapeutic strategies for reducing transmission of Plasmodium
vivax malaria. Advances in parasitology 2012, 80:271–300.
18. Sattabongkot J, Tsuboi T, Zollner GE, Sirichaisinthop J, Cui L: Plasmodium
vivax transmission: chances for control? Trends Parasitol 2004, 20:192–198.
19. Dapeng L, Leyuan S, Xili L, Xiance Y: A successful control programme for
falciparum malaria in Xinyang, China. Trans R Soc Trop Med Hyg 1996,
90:100–102.
Hsiang et al. Malaria Journal 2013, 12:383 Page 14 of 14
http://www.malariajournal.com/content/12/1/38320. Chen W, Wu K, Lin M, Tang L, Gu Z, Wang S, Lan C, Lan X, Li H, Huang M,
Chen X, Sheng H: [A pilot study on malaria control by using a new
strategy of combining strengthening infection source treatment and
health education in mountainous areas of Hainan province](in Chinese).
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1999, 17:1–4.
21. Tang LH, Qian HL, Xu SH: Malaria and its control in the People’s Republic
of China. Southeast Asian J Trop Med Public Health 1991, 22:467–476.
22. Tang LH: Progress in malaria control in China. Chin Med J 2000, 113:89–92.
23. Huang F, Zhou S, Zhang S, Li W, Zhang H: Monitoring resistance of
Plasmdium vivax: point mutations in dihydrofolate reductase gene in
isolates from Central China. Parasit Vectors 2011, 4:80.
24. Xu BL, Su YP, Shang LY, Zhang HW: Malaria control in Henan Province,
People’s Republic of China. Am J Trop Med Hyg 2006, 74:564–567.
25. Huang GQ, Yuan FY, Jin XL, Zhao CL, Su YP, Shen YZ: To analyze epidemic
situation and control of malaria in Jiangsu, Shandong, Henan, Anhui,
and Hubei province. Chin J Vector Biol Control 2007, 18:398–401.
26. Sleigh AC, Liu XL, Jackson S, Li P, Shang LY: Resurgence of vivax malaria in
Henan Province, China. Bull World Health Organ 1998, 76:265–270.
27. Zhou SS, Wang Y, Tang LH: [Malaria situation in the People’s Republic of
China in 2006](in Chinese). Zhongguo Ji Sheng Chong Xue Yu Ji Sheng
Chong Bing Za Zhi 2007, 25:439–441.
28. Zhang W, Wang L, Fang L, Ma J, Xu Y, Jiang J, Hui F, Wang J, Liang S, Yang
H, Cao W: Spatial analysis of malaria in Anhui province, China. Malar J
2008, 7:206.
29. Sihong County Centers for Disease Control and Prevention: Malaria anti-
relapse therapy guidelines. Sihong, Jiangsu, China: Sihong County Centers for
Disease Control and Prevention; 2008.
30. Jiangsu Institute of Parasitic Diseases: Jiangsu Province Malaria Records 1973-
1983. Wuxi, Jiangsu, China: Jiangsu Institute of Parasitic Diseases; 1984.
31. Xuyi County Centers for Disease Control and Prevention: Xuyi County
Malaria Reports 2000-2009. Xuyi, Jiangsu, China: Xuyi County Center for
Disease Control and Prevention; 2010.
32. Sihong County Centers for Disease Control and Prevention: Sihong County
Malaria Reports 2000-2009. Sihong, Jiangsu, China: Sihong County Centers
for Disease Control and Prevention; 2010.
33. Sihong County Centers for Disease Control and Prevention: Sihong Statistical
yearbooks 2000-2009. Sihong, Jiangsu, China: Sihong County Bureau of
Statistics; 2010.
34. Xuyi County Centers for Disease Control and Prevention: Xuyi Statistical
yearbooks 2000-2009. Xuyi, Jiangsu, China: Xuyi County Bureau of Statistics; 2010.
35. International Research Institute for Climate and Society: http://iridl.ldeo.
columbia.edu.
36. Stracci F, Canosa A, Minelli L, Petrinelli AM, Cassetti T, Romagnoli C, La Rosa
F: Cancer mortality trends in the Umbria region of Italy 1978-2004: a
joinpoint regression analysis. BMC Cancer 2007, 7:10.
37. Jiangsu Institute of Parasitic Diseases: Jiangsu Eight Main Counties, Malaria
Control Report. Wuxi, Jiangsu, China: Jiangsu Institute of Parasitic Diseases; 1984.
38. Jiangsu Institute of Parasitic Diseases: Primaquine adverse reaction: 9 case
reports, Jiangsu Province Schistosomiasis Prevention Research Center and Liuhe
County Health and Immunization Station, in: Selected Malaria Records from 1974-
1983. Wuxi, Jiangsu, China: Jiangsu Institute of Parasitic Diseases; 1984:122.
39. Jiangsu Institute of Parasitic Diseases: Primaquine causing hemolysis, 40 cases
report, Jiangsu Province Schistosomiasis Prevention Research Center and Liuhe
County Health and Immunization Station, in: Selected Malaria Records from 1974-
1983. Wuxi, Jiangsu, China: Jiangsu Institute of Parasitic Diseases; 1984:104–107.
40. Jiangsu Institute of Parasitic Diseases: Survey of family members: 3 cases,
Jiangsu Province Schistosomiasis Prevention Research Center and Liuhe County
Health and Immunization Station, in: Selected Malaria Records from 1974-
1983. Wuxi, Jiangsu, China: Jiangsu Institute of Parasitic Diseases; 1984:116.
41. Bian S, Li C, Zhang X, Huang B, Wang Y, Zhao L: Jiangsu Province Liuhe
Region Hereditary RBC G6PD Defect Preliminary Investigation Report, Jiangsu
Province Schistosomiasis Prevention Research Center and Liuhe County Health
and Immunization Station, in: Selected Malaria Records from 1974-1983. Wuxi,
Jiangsu, China: Jiangsu Institute of Parasitic Diseases; 1984:110–115.
42. Jiangsu Institute of Parasitic Diseases: Primaquine adverse event: 1 case report,
Jiangsu Province Schistosomiasis Prevention Research Center and Liuhe County
Health and Immunization Station, in: Selected Malaria Records from 1974-1983.
Wuxi, Jiangsu, China: Jiangsu Institute of Parasitic Diseases; 1984:121.
43. Yin JH, Yang MN, Zhou SS, Wang Y, Feng J, Xia ZG: Changing Malaria
Transmission and Implications in China towards National Malaria
Elimination Programme between 2010 and 2012. PLoS One 2013, 8:e74228.44. White NJ: Primaquine to prevent transmission of falciparum malaria.
Lancet Infect Dis 2013, 13:175–181.
45. Shanks GD: Control and elimination of Plasmodium vivax. Adv Parasitol
2012, 80:301–341.
46. Garfield RM, Vermund SH: Changes in malaria incidence after mass drug
administration in Nicaragua. Lancet 1983, 2:500–503.
47. World Health Organization: Interregional workshop on the control of vivax
malaria in East Asia, Shanghai, China, 2003. Regional Office for the Western
Pacific: World Health Organization; 2004.
48. WHO: Inter-regional meeting on vivax malaria in Asia. Regional Office for
South-East Asia: World Health Organization; 2009.
49. Simeons ATW: Follow-up of a mass treatment with injectable atebrin. Ind
Med Gaz 1938, 73:713–715.
50. Caceres JL: Malaria before and after massive radical cure in Sucre state,
Venezuela. Bol Malar Salud Ambi 2008, 48:83–90.
51. Gabaldon A, Guerrero L: An attempt to eradicate malaria by the weekly
administration of pyrimethamine in areas of out-of-doors transmission in
Venezuela. Am J Trop Med Hyg 1959, 8:433–439.
52. Greenwood BM: Control to elimination: implications for malaria research.
Trends Parasitol 2008, 24:449–454.
53. Ho C: Studies on malaria in new China. Chin Med J 1965, 84:491–497.
54. Okell LC, Griffin JT, Kleinschmidt I, Hollingsworth TD, Churcher TS, White MJ,
Bousema T, Drakeley CJ, Ghani AC: The potential contribution of mass
treatment to the control of Plasmodium falciparum malaria. PLoS One
2011, 6:e20179.
55. White NJ, Qiao LG, Qi G, Luzzatto L: Rationale for recommending a lower
dose of primaquine as a Plasmodium falciparum gametocytocide in
populations where G6PD deficiency is common. Malar J 2012, 11:418.
56. Jiang W, Yu G, Liu P, Geng Q, Chen L, Lin Q, Ren X, Ye W, He Y, Guo Y,
Duan S, Wen J, Li H, Qi Y, Jiang C, Zheng Y, Liu C, Si E, Zhang Q, Tian Q, Du
C: Structure and function of glucose-6-phosphate dehydrogenase-
deficient variants in Chinese population. Hum Genet 2006, 119:463–478.
57. Alving AS: Clinical treatment of malaria. US Army Medical Science
Publication No 4 1954, 22:210–218.
doi:10.1186/1475-2875-12-383
Cite this article as: Hsiang et al.: Mass drug administration for the
control and elimination of Plasmodium vivax malaria: an ecological
study from Jiangsu province, China. Malaria Journal 2013 12:383.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
